Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

5.72
-0.2400-4.03%
Pre-market: 5.58-0.1399-2.45%09:14 EST
Volume:3.51M
Turnover:20.49M
Market Cap:440.52M
PE:-4.27
High:6.09
Open:5.94
Low:5.71
Close:5.96
Loading ...

Company Profile

Company Name:
Altimmune, Inc.
Exchange:
NASDAQ
Establishment Date:
1997
Employees:
59
Office Location:
910 Clopper Road,Suite 201S,Gaithersburg,Maryland,United States
Zip Code:
20878
Fax:
- -
Introduction:
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Directors

Name
Position
Mitchel B. Sayare
Director and Chairman of the Board
Vipin K. Garg
President and Chief Executive Officer and Director
Catherine Sohn
Director
David J. Drutz
Director
Diane Jorkasky
Director
John M. Gill
Director
Klaus O. Schafer
Director
Philip L. Hodges
Director
Wayne Pisano
Director

Shareholders

Name
Position
Vipin K. Garg
President and Chief Executive Officer and Director
Richard Eisenstad
Chief Financial Officer
M. Scot Roberts
Chief Scientific Officer
M. Scott Harris
Chief Medical Officer
Raymond M. Jordt
Chief Business Officer